孙玉洁
.
发布人:gnjyadmin  发布时间:2021-03-19   动态浏览次数:2334

孙玉洁




        教授, 博导。1996年在德国维尔茨堡大学人类遗传所获理学博士学位,同年赴美国洛杉矶City of Hope National Medical Center,被聘为南京医科大学细胞生物系和医学遗传学系主任,校特聘教授。现为江苏省人类功能基因组学重点实验室和江苏高校肿瘤个体化医学协同创新中心肿瘤生物标志物与防治重点实验室PI, 南京医科大学细胞生物学系教授。

        课题组运用细胞生物学和分子生物学手段,结合临床样本和数据重点探讨:(1)增强子元件的调控功能、分子机制及遗传变异的肿瘤生物学效应;(2)肿瘤耐药的分子生物学和表观遗传学机制。回国以来主持国家自然科学基金项目、科技部973项目课题、江苏省重点招标项目等多项科研项目,并在Genome Biology,Nucleic Acid Research,Oncogene等国际学术期刊发表论文40余篇。 获江苏省科学技术进步二等奖一项,国家专利三项。

       现担任中华医学会医学细胞生物学会副主委,中国遗传学会理事中国遗传学会表观遗传专业委员会委员、江苏省医学会理事、江苏省遗传学会副会长和中国转化医学联盟常务理事等学术兼职。

在研项目课题

182072580,13q12.12肺癌风险染色质区TNFRSF19:一个新的肺癌抑癌基因的功能和机制研究,国家自然科学基金面上项目,202111-20241231日,负责人。

281874045,探讨13q12.12肺癌风险染色质区增强子遗传变异的生物学效应及机制,国家自然科学基金面上项目,201911 - 20221231日,负责人。

发表的主要文章

1. Lipei  Shao, Xianglin Zuo, Yin Yang, Yu Zhang, Nan Yang , Bin Shen,  Jianying Wang, Xuchun Wang, Ruilei , Guangfu Jin, Dawei Yu, Yuan Chen, Luan Sun , Zhen Li, Qiaofen Fu, Zhibin Hu, Xiao Han, Xin Song*, Hongbin Shen*, Yujie Sun*. The inherited variations of a p53-responsive-enhancer in 13q12.12 confer lung cancer risk by attenuating TNFRSF19 expression. Genome Biology, 2019 May 24; 20(1):103.

2. Si X, Liu Y, Lv J, Ding H, Zhang XA, Shao L, Yang N, Cheng H, Sun L, Zhu D, Yang Y, Li A, Han X, Sun Y*, ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells. Oncotarget, 2016 Apr 12; 7(15):20966-80.

3. Shi JF, Yang N, Ding HJ, Zhang JX, Hu ML, Leng Y, Han X, Sun YJ*, ERα directly activated the MDR1 transcription to increase paclitaxel-resistance of ERα-positive breast cancer cells in vitro and in vivo, Int J Biochem Cell Biol. 2014 Apr 28;53C:35-45.

4. Gong F, Sun L, Wang Z, Shi J, Li W, Wang S, Han X, Sun Y*. The BCL2 gene is regulated by a special AT-rich sequence binding protein 1-mediated long range chromosomal interaction between the promoter and the distal element located within the 3'-UTR. Nucleic Acids Res. 2011 Jun 1; 39(11): 4640-4652.

5. Wang T, Lv JH, Zhang XF, Li CJ, Han X, Sun YJ*. Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1. Int J Cancer. 2010 Jan 15; 126(2):362-70.

6. Ma C, Zhang J, Durrin LK, Lv J, Zhu D, Han X, Sun Y*. The BCL2 major breakpoint region (mbr) regulates gene expression. Oncogene. 2007 Apr 19; 26(18):2649-57.

7Sun Y, Durrin LK, Krontiris TG. Specific interaction of PML bodies with the TP53 locus in Jurkat interphase nuclei.Genomics. 2003 Aug;82(2):250-2.

8Sun Y, Wyatt RT, Bigley A, Krontiris TG. Expression and replication timing patterns of wildtype and translocated BCL2 genes. Genomics. 2001 Apr 15; 73(2):161-70.

9Sun YJ, Baumer A. Nonrandom X inactivation and selection of fragile X full mutation in fetal fibroblasts. Am J Med Genet. 1999 Sep 10; 86(2):162-4.

10. Seyschab H, Friedl R, Sun Y, Schindler D, Hoehn H, Hentze S, Schroeder-Kurth T. Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia.Blood. 1995 Apr 15;85(8):2233-7.

11. Seyschab H, Bretzel G, Friedl R, Schindler D, Sun Y, Hoehn H.Modulation of the spontaneous G2 phase blockage in Fanconi anemia cells by caffeine: differences from cells arrested by X-irradiation.Mutat Res. 1994 Jul 16;308(2):149-57.

12. Seyschab H, Sun Y, Friedl R, Schindler D, Hoehn H. G2 phase cell cycle disturbance as a manifestation of genetic cell damage.Hum Genet. 1993 Aug;92(1):61-8.